(E)-2-amino-7-(1-aminoethylideneamino)-2-methylhept-5-enoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (E)-2-amino-7-(1-aminoethylideneamino)-2-methylhept-5-enoic acid
• 化学式: C₁₀H₁₉N₃O₂
• 分子量: 213.28
• InChiKey: XRYVIWRHMIMIDT-HWKANZROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.9
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• 2-Amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
  申请人：——

  公开号：US20020132849A1

  公开（公告）日：2002-09-19

  The present invention relates to 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.

  本发明涉及2-氨基-2-烷基-5-庚烯酸和庚炔酸衍生物及其在治疗中的应用，特别是它们作为一氧化氮合酶抑制剂的用途。
• [EN] CRYSTALLINE SOLID FORM OF (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIC ACID<br/>[FR] FORME CRISTALLINE SOLIDE DE L'ACIDE (2S-5Z)-2-AMINO-7-(ETHANIMIDOYLAMINO)-2-METHYLHEPT-5-ENOIQUE
  申请人：PHARMACIA CORP

  公开号：WO2004018412A1

  公开（公告）日：2004-03-04

  (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid is crystallized as an anhydrous, stoichiometric 1.5 HCl salt and a scaleable crystallization method is disclosed. The salt form was characterized and the absolute configuration of the chiral center was confirmed as 'S'. (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5­enoic acid was high melting and appears acceptably non-hygroscopic for use in a pharmaceutical composition.

  (2S,5Z)-2-氨基-7-(乙烯基氨基)-2-甲基庚-5-烯酸以无水、化学计量比为1.5的盐酸盐形式结晶，并披露了一种可扩展的结晶方法。盐的形式进行了表征，并确认手性中心的绝对构型为'S'。(2S,5Z)-2-氨基-7-(乙烯基氨基)-2-甲基庚-5-烯酸具有高熔点，看起来在制药组合物中具有可接受的不吸湿性。
• 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
  申请人：Hansen W. Donald

  公开号：US20050113451A1

  公开（公告）日：2005-05-26

  The present invention relates to 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives and their use in therapy, in particular their use as nitric oxide synthase inhibitors.

  本发明涉及2-氨基-2-烷基-5-庚烯酸和庚炔酸衍生物及其在治疗中的应用，特别是它们作为一氧化氮合酶抑制剂的应用。
• Crystalline solid form of (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
  申请人：——

  公开号：US20040132822A1

  公开（公告）日：2004-07-08

  (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid is crystallized as an anhydrous, stoichiometric 1.5 HCl salt and a scaleable crystallization method is disclosed. The salt form was characterized and the absolute configuration of the chiral center was confirmed as “S”. (2S,5Z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid was high melting and appears acceptably non-hygroscopic for use in a pharmaceutical composition.

  (2S,5Z)-2-氨基-7-(乙脒酰氨基)-2-甲基庚-5-烯酸以无水、1.5 HCl 定量盐的形式结晶，并公开了一种可扩展的结晶方法。对盐的形式进行了表征，并确认手性中心的绝对构型为 "S"。(2S,5Z)-2-氨基-7-(乙脒酰氨基)-2-甲基庚-5-烯酸具有高熔点，并且在药物组合物中具有可接受的非吸湿性。
• [EN] FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS<br/>[FR] AMIDES DE PIPÉRIDINE FUSIONNÉS UTILES EN TANT QUE MODULATEURS DE CANAUX IONIQUES
  申请人：VERTEX PHARMA

  公开号：WO2015006280A9

  公开（公告）日：2015-05-14